It is probably the most common question we hear at a first weight management consultation at The Wright Practice. The honest answer is that it depends, but there is a clear pattern most patients follow, and understanding it makes the whole process easier to navigate.
This post walks through the typical timeline for Mounjaro (tirzepatide) and Wegovy (semaglutide) based on what clinical evidence shows and what we see in practice. It also covers the factors that can speed results up or slow them down, and what the programme at The Wright Practice looks like alongside the medication.
Mounjaro and Wegovy are both GLP-1 medications, a class of drug that works by mimicking a natural appetite hormone produced in the gut. GLP-1 (glucagon-like peptide-1) signals to the brain that you are full, slows how quickly food moves through the stomach, and helps regulate blood sugar after meals.
Wegovy contains semaglutide, which targets the GLP-1 receptor alone. Mounjaro contains tirzepatide, a dual-action medication that targets both the GLP-1 receptor and a second receptor called GIP (glucose-dependent insulinotropic polypeptide), which appears to amplify the appetite-suppressing effect. This is one reason clinical trial data shows Mounjaro producing slightly greater average weight loss at full dose.
Both are weekly self-injections, both require a medical assessment before starting, and both work best as part of a monitored programme, not as standalone prescriptions.
One of the most striking things patients describe in the first few weeks is a reduction in what many call food noise. This is the near-constant mental preoccupation with food: thinking about the next meal, struggling to feel satisfied, finding cravings hard to ignore even when not physically hungry.
For many people who have spent years fighting appetite, this shift is significant. Dr Dan Wright notes that patients often describe it not as feeling less hungry, but as food simply stopping to occupy so much mental space. Most notice this change between weeks two and four, usually before any major weight loss has occurred.
The reduction in food noise is driven by the medication’s effect on the brain’s appetite-signalling pathways, not by willpower or restriction. That distinction matters, because it reframes what treatment is actually doing: adjusting biology, not imposing deprivation.
The table below reflects the general arc most patients follow. Individual results vary, and factors including starting weight, dose, lifestyle and any underlying medical conditions all play a role.
| Timeframe | What typically happens | Starting dose. Body adjusting. |
|---|---|---|
Weeks 1-4(2.5mg) | Appetite shifts, food noise reduces. Smaller portions feel comfortable. Nausea most common in this phase. | Starting dose. Body adjusting. |
Weeks 4-8(5mg) | First noticeable weight loss for most patients. Energy may begin to improve. Cravings ease. | Dose increased if well tolerated. |
Weeks 8-16(7.5-10mg) | Steady weight loss, typically 0.5-1kg per week. Sleep and mobility often improve. Blood pressure may begin to fall. | Follow-up to review and escalate dose. |
Months 4-6(10-15mg) | Optimal dose range for most. Cumulative results more visible. Confidence and energy notable. | Dr Dan reviews at each step. |
6-12 months | Clinical trials show 15-22% body weight loss at full dose. Results vary by individual, lifestyle and medical history. | Ongoing monitoring continues. |
Before any prescription is written, Dr Dan Wright takes a thorough history covering medical background, any previous weight management attempts, current lifestyle, sleep, stress levels, and underlying contributors to weight gain. Blood tests are reviewed, and suitability for treatment is assessed carefully.
The programme itself involves:
We do not see Mounjaro or Wegovy as a quick fix. For most patients, the medication is most effective when combined with some attention to sleep, eating patterns and the factors that contributed to weight gain in the first place. The programme is designed around that view.
Patients often ask how long they will need to stay on the medication. There is no single answer. Some use it for a defined period to reach a target weight and then transition to maintaining that with lifestyle changes. Others find that ongoing low-dose treatment helps them sustain results long term. We discuss this openly, because the right approach varies from person to person.
Several factors can affect how quickly and consistently weight loss progresses:
The point is not to blame the patient when progress stalls. It is to understand the contributing factors and adjust the programme accordingly. This is why ongoing follow-up matters, not just the prescription.
Book a weight management consultation with Dr Dan Wright at The Wright Practice. We will spend time understanding your history, lifestyle and goals before recommending the right approach for you.
Most patients notice a shift in appetite and a reduction in food noise between weeks two and four, before significant weight loss has occurred. The first visible weight change typically appears by weeks six to eight. Results build gradually over several months as the dose is escalated.
Clinical trial data suggests Mounjaro (tirzepatide) produces slightly greater average weight loss over the same period, largely because it targets two appetite-regulating receptors rather than one. Individual response varies, and the right medication depends on your medical history, not the headline number. Dr Dan will discuss both options at your consultation.
Weight regain is common after stopping GLP-1 medications if lifestyle factors have not been addressed. The medications regulate appetite biology, but they do not permanently change the underlying drivers of weight gain. At The Wright Practice, we plan for this from the start, with a gradual dose reduction plan and honest discussion about long-term maintenance.
Nausea, mild fatigue and changes in digestion are the most common side effects, particularly in the first few weeks and after each dose increase. These usually settle within a week or two. Starting at the lowest dose and escalating slowly, as we do at The Wright Practice, reduces their impact. If side effects are significant, we adjust the plan.
Yes. Both medications are available privately at The Wright Practice following a medical assessment with Dr Dan Wright. NHS access to Mounjaro and Wegovy for weight management remains restricted and subject to eligibility criteria and waiting times. Private treatment allows faster access and a more closely monitored, personalised programme.
Rated ★ ★ ★ ★ ★ from 192 Reviews
